Drug Profile
TVAX cancer vaccine - TVAX Biomedical
Latest Information Update: 03 Jul 2023
Price :
$50
*
At a glance
- Originator TVAX Biomedical
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 29 Jun 2023 V2ACT Therapeutics has patent protection for methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy in USA
- 16 Dec 2020 No development reported - Phase-II for Brain cancer in USA (IV)
- 10 Oct 2016 Phase-II clinical trials in Brain cancer in USA (IV) before October 2016 (TVAX Biomedical pipeline, October 2016)